P1, N=50, Not yet recruiting, Stanford University | Initiation date: Feb 2026 --> Jun 2026

P=N/A, N=67, Active, not recruiting, Minia University

P2, N=120, Recruiting, Laboratoires Thea | Not yet recruiting --> Recruiting

P4, N=128, Completed, Chong Kun Dang Pharmaceutical | Unknown status --> Completed

P3, N=65, Terminated, University Hospital, Rouen | Completed --> Terminated; Difficulty in enrolling new patients

P1/2, N=96, Not yet recruiting, Xijing Hospital

Routine TDM was most frequently used for classical agents (methotrexate, cyclosporin A), antifungals, and antibiotics, but substantial interest was reported for targeted therapies, including BCL-2 inhibitors, BCR-ABL tyrosine kinase inhibitors, FLT3 inhibitors, and Bruton tyrosine kinase inhibitors. While firmly established for classical agents and anti-infectives, clinicians express growing interest in extending TDM to targeted therapies. Optimizing turnaround times, expanding assay availability, and integrating pharmacokinetics-informed dosing into clinical trials may further clarify the role of TDM within precision medicine approaches in hematology.

P=N/A, N=200, Recruiting, Masonic Cancer Center, University of Minnesota | Trial completion date: Feb 2027 --> Feb 2028 | Trial primary completion date: Feb 2026 --> Feb 2027

Treatment prioritized AA with cyclosporine and eltrombopag. Subsequently, the LPL/WM was treated with rituximab monotherapy...Although AA is a diagnosis of exclusion, its coexistence with lymphoma is rare. This case highlights the diagnostic and therapeutic complexity of AA and LPL/WM overlap and suggests that prioritizing the treatment of AA may lead to better outcomes.